The Company.
AUSTRALIAN-US BIOTECH COMPANY NOVAPEP IS DEVELOPING G10 AN AGONIST POLYPEPTIDE THAT MIMICS THE CELL SIGNALING ACTIVITY OF ACTIVATED PROTEIN C (APC).
Pioneers in APC & Peptide Mimetic Research.
The Founders behind Novapep’s
revolutionary Science.
Novapep’s co-founders, Profs John Griffin and Laurent Mosnier at The Scripps Research Institute in San Diego and Prof Chris Jackson at the University of Sydney, have conducted over 30 years of ground-breaking R&D in APC.
Prof Griffin and Prof Mosnier invented the PAR1 agonist peptide and Prof Mosnier developed the PAR3 agonist peptide. They subsequently developed G10 - the PAR1/PAR3 conjugated bivalent agonist peptide, which is proven to reduce activation of the NLRP3 inflammasome.
G10 Modifications.
Prof Akhter Hossain of The Florey Institute of Neuroscience and Mental Health is developing analogs of G10 with significantly increased half-life and stability - the NVP-300 Series for the treatment of severe community-acquired pneumonia
Prof Hossain's group has developed and published a cheaper and faster way to manufacture GLP-1 agonists with similar in vivo potency to semaglutide.